Triumvira Immunologics

Please note: The information displayed on this page might be outdated.
Triumvira Immunologics: A clinical-stage immunotherapy company intended to develop novel T-cell therapies that are safer and more efficacious than current cell therapy cancer treatments. The company's proprietary technology recruits the entire natural T-cell receptor and functions independent of the Major Histocompatibility Complex (MHC), potentially allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and with diseases other than cancer, thereby providing medical practitioners and patients with new hope to deal with life-threatening diseases.
Based in...
US - West South Central
Crystal Mountain At Barton Creek
Austin, TX 78733
United States

Company Participants at Spring Private Company Showcase

Paul Lammers
Triumvira Immunologics, President & CEO
Paul Lammers, MD, MSc, joined Triumvira Immunologics as President and CEO in January 2018. Before Triumvira, Dr. Lammers served as President & CEO at Mirna Therapeutics, for which company he raised $160 million through venture capital and Federal and State government funding, as well as a public listing on NASDAQ. Previously, he served as Chief Medical Officer and Head of US Product Development for EMD Serono. During his early industry tenure, Dr. Lammers also held various executive/senior management positions in clinical development, medical and regulatory affairs, at different pharmaceutical companies, as well as at small public and privately held biotech companies. Dr. Lammers serves as Lead Independent Director for publicly-traded Salarius Pharmaceuticals, and as Director for private biotech company, Immunomet.

Upcoming Company Event Participation